DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

• Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old  BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025    European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe Company to host investor conference call at 5:00pm ET today DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe.
• 10/22/2024

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

• Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28th, 2024 in Boston, Massachusetts. This year's meeting will feature a “Product Theater” on What Defines an Optimal Peanut Allergy Treatment?
• 10/18/2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

• Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin ® Peanut Patch in peanut allergic children ages 4 – 7 years old Topline results of VITESSE data are expected by Q4 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that patient screening is complete for the Phase 3 trial, VITESSE ( V iaskin Peanut I mmunotherapy T rial to E valuate S afety, S implicity and E fficacy), using the modified Viaskin Peanut Patch in children ages 4 – 7 years old with peanut allergy. “We are thrilled to have reached this significant milestone,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies.
• 09/23/2024

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

• Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C.
• 09/04/2024

DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q2 2024 Earnings Conference Call July 30, 2024 5:30 PM ET Company Participants Katie Matthews – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Virginie Boucinha – Chief Financial Officer Conference Call Participants Jon Wolleben – Citizens JMP Operator Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call.
• 07/30/2024

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

• Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.
• 07/30/2024

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

• Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT Toddlers DBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today shared an update on the Phase 3 study, VITESSE ( V iaskin Peanut I mmunotherapy T rial to E valuate S afety, S implicity and E fficacy), using the modified Viaskin Peanut Patch, in children ages 4 – 7 years old with peanut allergy. The Company also provided a status update on the COMFORT (Characterization of the Optimal Management of FOod allergy Relief and Treatment) Toddlers supplemental safety study in 1 – 3-year-olds with peanut allergy.
• 07/30/2024

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

• Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.
• 07/29/2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

• AMF Regulated Information Montrouge, France, July 8, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2024: 303,744 DBV Technologies shares, € 62,415.60 When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account: 41,159 DBV Technologies shares, € 432,367.25.
• 07/08/2024

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

• Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10th, at 8:00 am EDT, as well as in one-on-one investor meetings. A live webcast of the presentation can be accessed here, and will also be available on the Events section of Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 days after the event.
• 06/05/2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

• Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the “ADS Ratio Change”) to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Change will be effective on or about June 7th, 2024 (the “Effective Date”).
• 05/31/2024

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

• Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation by Nicolette Arends, M.D.
• 05/30/2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

• Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about June 3rd, 2024 (the “Effective Date”).
• 05/17/2024

DBV Technologies Announces Results of its 2024 Combined General Meeting

• Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
• 05/16/2024

DBV Technologies to Participate in Upcoming Investor Conferences

• Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024 Format:         Fireside Chat Time:             11:00am ETLocation:       Hilton Midtown Hotel, New York, NY H.C.
• 05/09/2024

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

• Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pietrusko, PharmD to Chief Regulatory Officer Q1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024.
• 05/07/2024

Combined General Meeting of May 16, 2024

• Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May 16, 2024, at 10:00 a.m. CET at the Company's new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.
• 04/25/2024

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

• Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com.
• 03/08/2024

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

• Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Strengthened executive leadership team in preparation for BLA submission Reported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. The audit procedures have been substantially completed by the Company's statutory auditors and financials – prepared under both US GAAP and IFRS for the purpose of Form 10-K and Universal Registration Document respectively – were approved by the Board of Directors on March 7, 2024.
• 03/07/2024

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

• Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.
• 03/04/2024

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

• Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D.
• 02/20/2024

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

• AMF Regulated Information Montrouge, France, January 16, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF. Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2023: 222,988 DBV Technologies shares, € 150,264.71.
• 01/16/2024

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

• The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
• 12/01/2023

Down -25.23% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

• DBV Technologies S.A. (DBVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
• 11/27/2023

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

• Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
• 11/09/2023

DBV Technologies to Present New Data at ACAAI 2023

• Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
• 11/02/2023

DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Rajan Sharma - Goldman Sachs Operator Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call.
• 10/31/2023

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

• Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies. Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used.
• 10/31/2023

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

• Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.
• 10/27/2023

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

• Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee.
• 10/16/2023

DBV Technologies to Participate in Upcoming Investor Conference

• Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY.
• 09/05/2023

DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q2 2023 Earnings Call July 31, 2023 5:00 PM ET Company Participants Katie Matthews - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Pharis Mohideen - Chief Medical Officer Conference Call Participants Jon Wolleben - JMP Securities Operator Good afternoon, and welcome to the DBV Technologies Second Quarter Financial Results Conference Call.
• 07/31/2023

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

• GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'); if (extendedTableZoomElements && extendedTableZoomElements.length > 0) { window.Stickyfill.add(extendedTableZoomElements); } const socialMediaSideBarContainerElement = document.querySelectorAll('.social-media-side-bar-container'); if (socialMediaSideBarContainerElement && socialMediaSideBarContainerElement.length > 0) { window.Stickyfill.add(socialMediaSideBarContainerElement); } }, false); window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ERWPGTJ5X8'); Accessibility: Skip TopNav // used in ui component window.pnrApplicationSettings = { Application:"pnr", SelectedLocale: 'en-US', PnrHostUrl: 'https://www.globenewswire.com', IsAuthenticated: false, ContextUser: '', ApplicationUrl: 'https://www.globenewswire.com', PageContext: '', SubscriptionId: 0, SubscriptionName: '', ArticleLogoUrl: '', ArticleHeadline: '', IsMobileVersion: 'False' === "True" ? true : false, HideLanguageSelection : false, NewsSearchHeading: '', ArticleMediaAttachments: [], AuthSessionExpirationMinutes: '0', AppLogoUrl: 'https://www.globenewswire.com/content/logo/color.svg', ReaderForgotPasswordUrl: 'https://pnrlogin.globenewswire.com/en/reset/confirmresetpassword', ReaderRegisterUrl: 'https://pnrlogin.globenewswire.com/en/register', IsQuickSignInEnabled: true, ReaderAccountBaseUrl: '' }; We're sorry, you encountered a page that doesn't exist.
• 07/31/2023

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

• Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.
• 07/25/2023

DBV Technologies to Participate in Upcoming Investor Conference

• Montrouge, France, June 06, 2023 DB V Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference taking place on June 12th – 15th in Dana Point, CA. Daniel Tassé, Chief Executive Officer, will engage in a Fireside Chat session on Wednesday, June 14th at 10:00am PST (1:00pm EST), as well as one-on-one investor meetings throughout the day.
• 06/06/2023

Why Shares of DBV Technologies Jumped Thursday

• The company's peanut allergy treatment patch could have a wide impact. DBV Technologies currently has no marketed products.
• 05/11/2023

DBV Technologies to Participate in Upcoming Investor Conference

• Montrouge, France, May 9, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences Conference taking place May 15-16 in New York, NY. Daniel Tassé, Chief Executive Officer, will make a company presentation on Monday, May 15, 2023 at 9:00am ET, as well as participate in one-on-one investor meetings throughout the day.
• 05/09/2023

7 Penny Stocks Sitting in the Sweet Spot

• While penny stocks almost always attract investors' attention at some point, they're also wildly unpredictable and risky. Yes, some people do enjoy lifechanging profitability.
• 03/26/2023

DBV Technologies S.A. (DBVT) Q4 2022 Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q4 2022 Results Conference Call March 2, 2023 5:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants Jon Wolleben - JMP Operator Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call.
• 03/03/2023

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

• Montrouge, France, February 27, 2023
• 02/27/2023

DBV Technologies to Participate in Upcoming Investor Conference

• Montrouge, France, February 10, 2023
• 02/10/2023

Why DBV Technologies Stock Is Soaring Today

• The company can now move forward with a late-stage study of its lead pipeline candidate.
• 12/23/2022

DBV Technologies: Downgrade And Tax Loss Selling Create A Buying Opportunity

• DBVT was recently downgraded by Goldman Sachs. It is trading lower on any timeframe you consider and hence makes a good tax loss buy candidate.
• 12/19/2022

DBV Technologies to Participate in Upcoming Investor Conference

• Montrouge, France, November 22, 2022
• 11/22/2022

DBV Technologies S.A. (DBVT) Q3 2022 Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q3 2022 Earnings Conference Call November 4, 2022 5:00 PM ET Company Participants Anne Pollak – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Conference Call Participants Jon Wolleben – JMP Securities Clément Bassat – Portzamparc Jacob Mekhael – Kempen Matthew Caufield – H.C.
• 11/06/2022

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

• Montrouge, France, October 31, 2022
• 10/31/2022

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

• DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA.
• 09/23/2022

DBV Technologies to Present at Upcoming Investor Conferences

• Montrouge, France, September 2, 2022
• 09/02/2022

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

• Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
• 08/23/2022

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

• DBV Technologies is a French company traded on Nasdaq which is developing treatments for food allergies. Their technology is a patch that delivers a very small daily dose of the allergen to desensitize the patient.
• 07/07/2022

2 Biotechs That Recently Soared -- Are They Buys?

• Let's consider the risk-reward profile of these companies before jumping on the bandwagon.
• 06/30/2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

• Montrouge, France, June 16, 2022
• 06/16/2022

Why DBV Technologies Stock Popped Again Today

• The French biotech kept its upward momentum going with news of nearly $200 million in fresh funding.
• 06/09/2022

Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?

• Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
• 06/09/2022

Why DBV Technologies Was a Big Winner on Wednesday

• Its peanut allergy patch tests quite well in very young patients.
• 06/08/2022

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

• HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage of treatment responders in the active compared to the placebo arm.
• 06/08/2022

DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In Toddlers

• DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint.  Viaskin Peanut demonstrated a statistically significant treatment effect, with 67.0% of subjects in the.
• 06/08/2022

Penny Stocks to Buy With Gains in After Hours? 3 to Watch

• Check these three penny stocks out for your watchlist The post Penny Stocks to Buy With Gains in After Hours? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
• 06/07/2022

Hot Penny Stocks You Need to Know About This Month

• Are these penny stocks on your watchlist right now? The post Hot Penny Stocks You Need to Know About This Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
• 05/04/2022

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q1 2022 Results - Earnings Call Transcript

• DBV Technologies S.A. (NASDAQ:DBVT ) Q1 2022 Results Conference Call May 2, 2022 5:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Operator Welcome to the DBV Technologies First Quarter 2022 Earnings Conference Call.
• 05/02/2022

Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

• Montrouge, France, April 26, 2022 DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments
• 04/25/2022

DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference

• Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference
• 03/14/2022

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2021 Results - Earnings Call Transcript

• DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2021 Results - Earnings Call Transcript
• 03/03/2022

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

• Montrouge, France, February 24, 2022
• 02/24/2022

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

• Montrouge, France, February 14, 2022
• 02/14/2022

DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

• Montrouge, France, January 7, 2022
• 01/07/2022

Why DBV Technologies Stock Is Down Sharply on Tuesday

• The road ahead for the peanut allergy treatment Viaskin Peanut is going to be rockier than investors had hoped.
• 12/21/2021

DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low

• After reviewing the FDA's information requests and considering all other options, DBV Technologies (NASDAQ: DBVT) has decided not to pursue the sequential approach to develop Viaskin Peanut (allergen uptake/transport study before STAMP).  DBV estimates that heeding to the FDA's newly proposed sequential approach would require at least five rounds of exchanges requiring FDA alignment before initiating STAMP, a 6-month safety, and adhesion study.
• 12/21/2021

DBV Technologies to Participate in an Upcoming Investor Conference

• Montrouge, France, November 24, 2021
• 11/24/2021

Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

• DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
• 11/17/2021

Why DBV Technologies Stock Is Jumping Today

• The company plans to announce new data for its experimental peanut allergy drug this week.
• 11/01/2021

Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

• DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
• 11/01/2021

DBV Technologies Shares Down On FDA Update For Its Peanut Allergy Program

• DBV Technologies (NASDAQ: DBVT) has received communication from the FDA concerning the STAMP protocol submission for its modified Viaskin Peanut (mVP) development program. The agency would like to review DBV's protein uptake release study data before providing additional comments on the STAMP protocol design.
• 10/27/2021

DBV Technologies to Participate at Upcoming Investor Conferences

• Montrouge, France, August 31, 2021
• 08/31/2021

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

• AMF REGULATED INFORMATION Montrouge, France, August 6, 2021
• 08/06/2021

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q2 2021 Results - Earnings Call Transcript

• DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q2 2021 Results - Earnings Call Transcript
• 08/02/2021

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

• Montrouge, France, August 2, 2021
• 08/02/2021

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

• Montrouge, France, July 26, 2021
• 07/26/2021

DBV Technologies to Present at Upcoming Investor Conferences

• Montrouge, France, June 2, 2021
• 06/02/2021

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D.

• Montrouge, France, May 19, 2021
• 05/19/2021

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

• Montrouge, France, May 5, 2021
• 05/05/2021

DBV Technologies Reports Q1 2021 Financial Results

• Montrouge, France, May 3, 2021
• 05/03/2021

DBV Technologies to Participate in Upcoming Investor Conferences

• Montrouge, France, April 29, 2021
• 04/29/2021

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

• Montrouge, France, April 28, 2021
• 04/28/2021

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

• Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
• 04/02/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

• Monthly information regarding the total number of voting rights and
• 04/01/2021

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

• Montrouge, France, March 26, 2021
• 03/26/2021

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

• Montrouge, France, March 17, 2021
• 03/17/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

• Monthly information regarding the total number of voting rights and
• 03/12/2021

Why DBV Technologies Stock Is Rising Today

• The company released its latest quarterly update, and investors liked what they saw.
• 03/12/2021

DBVT Stock Price Increases Over 10% Pre-Market: Why It Happened

• The stock price of DBV Technologies (NASDAQ: DBVT) has increased by over 10% pre-market. This is why it happened.
• 03/12/2021

DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2020 Results - Earnings Call Transcript

• DBV Technologies S.A. (DBVT) CEO Daniel Tassé on Q4 2020 Results - Earnings Call Transcript
• 03/11/2021

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

• Montrouge, France, March 11, 2021
• 03/11/2021

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

• Montrouge, France, March 5, 2021
• 03/05/2021

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

• Montrouge, France, March 3, 2021
• 03/03/2021

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

• Montrouge, France, February 24, 2021
• 02/24/2021

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

• Montrouge, France, February 22, 2021
• 02/22/2021

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

• Montrouge, France, February 19, 2021
• 02/19/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

• Monthly information regarding the total number of voting rights and
• 02/11/2021

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

• AMF REGULATED INFORMATION Montrouge, France, January 29, 2021
• 01/29/2021

Why DBV Technologies Stock Popped Today

• After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
• 01/15/2021

DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News

• DBV Technologies (DBVT) stock is soaring higher on Friday after providing an update on its upcoming peanut allergy treatment. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy Patch News appeared first on InvestorPlace.
• 01/15/2021

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

• Montrouge, France, January 14, 2020
• 01/14/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

• Monthly information regarding the total number of voting rights and
• 01/05/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

• Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020
• 12/15/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

• Monthly information regarding the total number of voting rights and 
• 11/11/2020

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

• Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin ™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020
• 11/10/2020

DBV Technologies to Participate in Upcoming Investor Conferences

• Montrouge, France, November 9, 2020 DBV Technologies to Participate in Upcoming Investor Conferences
• 11/09/2020

Why DBV Technologies Stock Is Soaring Today

• The company submitted its potential peanut allergy treatment for review in Europe.
• 11/02/2020

Is This Peanut Allergy Treatment Back on the Table?

• DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was validated by the European Medicines Agency (EMA).
• 11/02/2020

DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency 

• Montrouge, France, November 2, 2020
• 11/02/2020

DBV Technologies Reports September 30, 2020 Cash Position

• Montrouge, France, October 30, 2020
• 10/30/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

• Monthly information regarding the total number of voting rights and  total number of shares of the Company as of July 31, 2020(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)Market : NYSE Euronext Paris ISIN Code: FR 0010417345  Date  Total number of shares Total number of voting rights 07/31/202054,927,187  Total gross of voting rights: 54,927,187     Total net* of voting rights: 54,867,787   * Total net = total number of voting rights attached to shares – shares without voting rightsAttachment * PDF Version
• 08/12/2020

Could This Small-Cap Biotech Stock Make You Rich?

• Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
• 08/11/2020

DBV discloses FDA concerns about experimental peanut allergy treatment

• Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its experimental peanut allergy treatment. The regulator asked for a new study stemming from its concerns about the efficacy of the Viaskin Peanut patch. "Given the uncertainty regarding the timeline for BLA resubmission, we are taking a conservative approach and pushing Viaskin Peanut launch out by two years," SVB Leerink's Joseph Schwartz wrote in a note to investors on Tuesday. In January the FDA approved Aiummune Therapeutics Inc.'s Palforzia, the first peanut allergy treatment. It is an oral immunotherapy. DBV's stock is down 76.2% since the start of the year, compared with the S&P 500 , which has gained 2.3%.
• 08/05/2020

SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC

• Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. ("DBV Technologies" or the "Company") (NASDAQ: DBVT) complied with federal securities laws. On August 4, 2020, DBV Technologies announced it had received a CRL letter from the FDA outlining concerns regarding the efficacy and corresponding need for further testing of the Company’s BLA for Viaskin Peanut. The price of DBV Technology’s stock fell following the announcement.
• 08/04/2020

Why DBV Technologies Stock Is Plunging Today

• Shares of DBV Technologies (NASDAQ: DBVT) were down a whopping 41.6% as of 11:41 a.m. EDT on Tuesday. The catalyst for this sell-off was the company's announcement that it has received a complete response letter from the Food and Drug Administration regarding its Biologics License Application (BLA) for Viaskin, a potential treatment for peanut allergy. DBV Technologies complied with this request, but it seems it wasn't enough to please the FDA.
• 08/04/2020

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

• Montrouge, France, August 4, 2020DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 YearsDBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the Company’s Biologics License Application (BLA) for investigational Viaskin™ Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.The Complete Response Letter indicates that the FDA cannot approve the application in its present form. The FDA has identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study. The FDA has also indicated that supplementary clinical data would need to be generated to support the modified patch. In addition, the FDA requested additional Chemistry, Manufacturing and Controls data. The Agency did not raise any safety concerns related to Viaskin Peanut.DBV intends to request a meeting with FDA to discuss the FDA’s comments as well as requirements for additional clinical data that may be needed to support BLA resubmission. The Company anticipates providing an update following this meeting, including updated cash runway resulting from the recent restructuring announced on June 26, 2020.“We are very disappointed in the FDA’s response, but continue to believe in the potential of Viaskin Peanut. Peanut allergy is one of the most common food allergies, and accidental exposure can result in life threatening reactions,” Daniel Tassé, Chief Executive Officer of DBV Technologies, stated. “We plan to fully collaborate with the FDA with regards to the outstanding issues and believe that the EPIT patch technology platform lends itself well to potential modifications to enhance patch functionality. We remain dedicated in our mission to develop innovative treatments for patients with food allergies.” About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical trial of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).Forward Looking Statements This press release may contain forward-looking statements and estimates, including statements regarding the potential benefits of Viaskin Peanut, anticipated regulatory interactions and our ability to modify the EPIT patch as may be necessary to address comments raised by the FDA in the CRL. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.DBV Contact Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 sara.sherman@dbv-technologies.comAttachment * PDF Version
• 08/04/2020

DBV Technologies Reports First Half 2020 Financial Results

• Montrouge, France, July 31, 2020DBV Technologies Reports First Half 2020 Financial ResultsDBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2020 financial results. The interim financial report is available on the Investor Relations section of the Company’s website, www.dbv-technologies.com/investor-relations/. First half 2020 financial statements were subject to a limited review by the Company’s external auditors.“In the first half of this year, we focused on working with FDA and submitting a robust data package to support its review of Viaskin Peanut. We also executed a restructuring to extend our runway and better position our business to prepare to bring this important treatment to patients,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “Recently, we published encouraging results from the PEOPLE Phase III open-label extension study of Viaskin Peanut in The Journal of Allergy and Clinical Immunology, highlighting the robust, long term clinical benefit of Viaskin Peanut with a decrease in adverse events among children with peanut allergy. We expect to hear from FDA on next steps with our BLA filing imminently and look forward to providing an update at that time.” * Cash Position: cash and cash equivalents as of June 30, 2020 were €225.9 million, compared to €172.0 million as of December 31, 2019, an increase of €53.8 million. In the first half 2020, cash used in operating activities was €(79.4) million and cash flows from investment activities were €(1.3) million, partially offset by an increase of €134.2 million in cash from financing activities received in connection with the Company’s February 2020 public offering.   * Operating Income: operating income was €7.6 million for the first half 2020 compared to €7.1 million for the first half 2019. In the first half 2020, as well as in the first half 2019, income was primarily generated from the Company’s Research Tax Credit (Crédit d’Impôt Recherche) and by income recognized under the Company’s collaboration agreement with Nestlé Health Science.   * Restructuring Costs: restructuring costs, related to the global restructuring announced on June 26, 2020, were €19.3 million for the first half of 2020 including accrued severance-related expenses as a result of anticipated organizational changes. DBV announced on June 26, 2020 that it was implementing a restructuring plan that will provide the flexibility to continue the BLA review process, prepare to bring Viaskin™ Peanut to patients, if approved, and preserve the Company’s cash runway. DBV had no restructuring costs in the first half of 2019.   * Research & Development Expenses: research and development expenses decreased by €3.9 million, or 7.5%, to €48.3 million in the first half 2020 compared to €52.2 million in the first half 2019, reflecting a decrease in personnel expenses, including headcount as well as accrued bonus, retention measures and share-based compensation expenses, as part of the announced restructuring plan.   * Sales & Marketing Expenses: sales and marketing expenses were €6.4 million for the first half 2020 compared to €8.3 million for the first half 2019, reflecting a decrease of €1.9 million, or 23.4%. The decrease in sales and marketing expenses resulted from a decrease in personnel expenses, including accrued bonus, retention measures and share-based compensation expense, as part of the announced restructuring plan. These decreases were partially offset by an increase in fees related to marketing tools and services for the potential commercialization of Viaskin Peanut in North America, if approved.   * General & Administrative Expenses: general and administrative expenses were €19.4 million for the first half 2020 compared to €25.8 million for the first half 2019, a decrease of €6.4 million, or 24.8%, resulting from a decrease in accrued bonus, retention measures and share-based compensation expense, as part of the announced restructuring plan. These decreases were partially offset by an increase in consulting and legal fees.   * Net Loss: net loss was €(86.5) million for the first half 2020, compared to €(79.8) million for the first half 2019. Loss per share (based on the weighted average number of shares outstanding over the period) was €(1.62) and €(2.43) in the first half 2020 and 2019, respectively.About DBV Technologies DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut (DBV712). DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).Forward Looking Statements This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut (DBV712) as a treatment for peanut-allergic children and the Company’s planned interactions with the FDA regarding Viaskin Peanut and the target action date for the Company’s BLA. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.DBV Contact Sara Blum Sherman Senior Director, Investor Relations & Strategy +1 212-271-0740 sara.sherman@dbv-technologies.comAttachment * PDF Version
• 07/31/2020

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

• Montrouge, France, July 20, 2020 AMF REGULATED INFORMATION Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN:.
• 07/20/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

• Monthly information regarding the total number of voting rights and  total number of shares of the Company as of June 30, 2020 (Article 223-16 of the General Regulations of.
• 07/15/2020

DBV Technologies' Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

• DBVT reports positive extension study data. Amneal receives FDA approval for Generic Fluphenazine Hydrochloride.
• 07/13/2020

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

• Montrouge, France, July 7, 2020 DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and.
• 07/10/2020

Here is What Hedge Funds Think About DBV Technologies SA (DBVT)

• The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
• 07/08/2020

The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts

• Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) * Cardiff Oncology Inc (NASDAQ: CRDF) * Cerus Corporation (NASDAQ: CERS) * Dynavax Technologies Corporation (NASDAQ: DVAX) * ESSA Pharma Inc (NASDAQ: EPIX) * Fennec Pharmaceuticals Inc (NASDAQ: FENC) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Immunovant Inc (NASDAQ: IMVT) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Keros Therapeutics Inc (NASDAQ: KROS) * KITOV PHARMA LT/S ADR (NASDAQ: KTOV) * Liquidia Technologies Inc (NASDAQ: LQDA) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Novavax, Inc. (NASDAQ: NVAX) * Ocular Therapeutix Inc (NASDAQ: OCUL) * ORIC Pharmaceuticals Inc (NASDAQ: ORIC) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Protagonist Therapeutics Inc (NASDAQ: PTGX) * Relmada Therapeutics Inc (NASDAQ: RLMD) * Replimune Group Inc (NASDAQ: REPL) * ResMed Inc. (NYSE: RMD) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * United Therapeutics Corporation (NASDAQ: UTHR) (Wedbush maintained a Buy rating on the shares) * Vaxart Inc (NASDAQ: VXRT) (announced a manufacturing partnership with Attwill Medical Solutions for its COVID-19 vaccine) * West Pharmaceutical Services Inc. (NYSE: WST) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 25) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Zogenix Seizure Drug Approved With REMS Restriction Zogenix, Inc. (NASDAQ: ZGNX) said the FDA has approved its Fintepla oral solution, CIV, for the treatment of seizures associated with Dravet syndrome in patients 2 and older. The company said the drug will be launched through a restricted distribution program, the FINTEPLA Risk Evaluation and Mitigation Strategy Program, and is expected to be available through its specialty pharmacy partner by the end of July.The stock was rallying by 16.54% to $32.77 premarket Friday. MediciNova Announces Publication Of Positive Preclinical Data For MN-166 In Glioblastoma MediciNova, Inc. (NASDAQ: MNOV), which recently announced a European intent to grant patent, announced positive preclinical findings published in Frontiers in Immunology regarding the prospect of MN-166 as an adjunct treatment for glioblastoma.In premarket trading, the stock was higher by 13.07% at $6.40. Altimmune Shares Gain On Fund Buying Altimmune Inc (NASDAQ: ALT) shares rose after Venrock Healthcare Partners II disclosed in a SEC filing a 20.8% stake in Altimmune as of June 15.The stock was up 24.05% at $11.40 premarket. See also: The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions AbbVie's Allergan Unit Gets Complete Response Letter For Eye Disorder Drug AbbVie Inc's (NYSE: ABBV) Allergan unit and and Molecular Partners said the FDA has issued a Complete Response Letter to the BLA for Abicipar pegol, an investigational DARPin therapy for patients with neovascular age-related macular degeneration.The FDA said the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk, prompting the CRL. AbbVie said it plans to meet with the FDA to discuss its comments and determine next steps.In premarket trading Friday, AbbVie shares were adding 0.52% to $97.49. DBV Announces Cost Cuts, Including Workforce Reduction The FDA has yet to decide on the BLA from DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) for its peanut allergy skin patch. The company said it is initiating a global and comprehensive restructuring plan that includes a significant reduction in workforce.The company said it is contemplating cost reduction measures across the organization while preserving core activities and competencies.DBV said it now expects its balance of cash and cash equivalents of 262.4 million euros ($294.2 million) at the end of the first quarter of 2020 will be sufficient to fund operations significantly beyond the prior guidance of the first quarter of 2021.The stock was sliding 15% to $4.59 in premarket trading Friday.Keros To Join Russell 2000 Index Keros said it is set to join the Russell 2000 Index effective after the close of the U.S. markets June 26.Axsome Gets Breakthrough Therapy Designation For AXS-05 Axsome Therapeutics Inc (NASDAQ: AXSM) said the FDA has granted Breakthrough Therapy designation for AXS-05 for the treatment of Alzheimer's disease agitation.In premarket trading Friday, the stock was adding 9.61% to $83.97.Offerings Milestone Scientific Inc. (NYSE: MLSS) priced its underwritten offering of 6.52 million shares of its common stock and warrants to purchase up to an aggregate of 3.26 million shares of its common stock.Each share of common stock is being sold together with a warrant to purchase 0.5 of a share at a combined price of $2.15. The company expects to raise gross proceeds of $14 million from the offering. The offering is expected to close on or about June 30.The stock was down 18.37% to $2 premarket Friday.Medical device maker Soliton Inc. (NASDAQ: SOLY) announced that it intends to offer shares of its common stock in an underwritten public offering.In premarket trading Friday, the stock was plunging 16.03% to $9.95. On The Radar PDUFA Dates The FDA is also expected to rule on Chiasma Inc's (NASDAQ: CHMA) NDA for Mycapssa, which is being evaluated as a maintenance therapy for acromegaly.Heron Therapeutics Inc (NASDAQ: HRTX) is awaiting an FDA nod for its HTX-011 as a treatment option for post-operative pain.Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has a PDUFA date of June 26 for the NDA for its NASH drug candidate obeticholic acid. With an Adcom meeting originally scheduled for June 9 having been postponed, it is less likely that an approval will come through.IPOs Fusion Pharmaceuticals. a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, priced its initial public offering of 12.5 million shares at $17 per share, above the estimated price range of $14-$16. The shares are to be listed on the Nasdaq under the ticker symbol "FUSN."Akouos, Inc., which is developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people who live with disabling hearing loss, priced its IPO of 12.5 million shares at $17 per share. The shares will be listed on the Nasdaq under the ticker symbol "AKUS."PolyPid Ltd, a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, priced its IPO of 3.75 million shares at $16 per share compared to the estimated price range of $15-$17. The shares will begin trading on the Nasdaq under the ticker symbol "PYPD."Related Link: Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug See more from Benzinga * The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
• 06/26/2020

DBV Technologies Provides Operational and Business Update

• DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that given the Company has not yet received an update from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Viaskin™ Peanut, it has undergone a comprehensive business review to best position DBV for the possibility of a delay in timelines for the Viaskin Peanut BLA review. As a result, the Board of Directors has approved the immediate initiation of a global and comprehensive restructuring plan, which is expected to include a significant reduction in workforce.
• 06/26/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

• Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (Article 223-16 of the General Regulations of the.
• 06/11/2020

20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

• 06/10/2020

40 Stocks Moving in Friday's Pre-Market Session

• 06/05/2020

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

• Montrouge, France, June 4, 2020 DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 Virtual.
• 06/04/2020

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

• Montrouge, France, June 2, 2020 DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345.
• 06/02/2020

DBV Technologies To Present at the Goldman Sachs 4–st Annual Global Healthcare Conference

• 06/02/2020

28 Stocks Moving in Thursday's Pre-Market Session

• 05/21/2020

20 Healthcare Stocks Moving In Thursday's Pre-Market Session

• 05/21/2020

61 Biggest Movers From Yesterday

• 05/20/2020

44 Stocks Moving In Tuesday's Mid-Day Session